NEVVI Medicare utilization intelligence

← back

SNEDDEN, TYLERM.D. NPI 1780002758 Clinician

Hematology-Oncology · WACO, TX

Specialty Hematology-Oncology — from billed Medicare claims
Trained UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON — medical school, self-reported to CMS
In practice about 12 years since medical school (class of 2014, self-reported to CMS)
Location WACO, TX · NPPES registered location
Active in data Billed Medicare 2020–2024 (5 consecutive years)
Scale 41 codes billed · 37,567 disclosed services (CY2024 — most recent year in data)
Current groups

Group affiliation since 2019

20212026
TEXAS ONCOLOGY PA
2021–2026

The roster archive begins in 2019, so a span starting at 2019 may reach back further. Membership spans only — no volume is attributed to any group here.

NPPES registry · CMS Doctors & Clinicians registry · Medicare Part B physician/supplier claims · NPPES record last updated 2022-01

Year: 2024 · 2023 · 2022  · 2021  · 2020 

Provider overview · all codes · CY2024

The full analytics for this provider

Premium

The billed-volume positioning, practice focus, and economics behind this provider — computed on the same disclosed Medicare Part B data.

This provider's disclosed Medicare payments across all codes were in CY2024. Unlock to see the figure.

  • Payment, service & beneficiary totals — the disclosed scale, all codes
  • Practice profile — focus & reach — top codes by share of services
  • Office vs. facility setting mix — place-of-service code split
  • Volume over five years — discrete yearly counts, no rate
  • Peer positioning — service volume — percentile among specialty peers, cohort & year disclosed
  • Peer positioning — code breadth — how many codes billed, vs peers

Peer positioning shows billed-volume and code-breadth positions among specialty peers, not measures of care (a provider's true volume position can only be higher, never lower). All figures disclosed Medicare Part B fee-for-service; volumes are personal to this NPI, not attributed to any group.

Notify me at launch → Or see a live example profile →

Procedures billed to Medicare Part B (2024)

Medicare Part B FFS · CY2024 · as published by CMS
CodeDescription Services Beneficiary-episodes Avg charge Avg Medicare payment
Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)
J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use)
Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml
J9267 Injection, paclitaxel, 1 mg
36415 Insertion of needle into vein for collection of blood sample
J1100 Injection, dexamethasone sodium phosphate, 1 mg
85025 Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count
99214 Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more
J2469 Injection, palonosetron hcl, 25 mcg
99213 Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more
G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's
G6015 Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session
96375 Injection of additional new drug or substance into vein
96413 Administration of chemotherapy into vein, 1 hour or less
99215 Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more
96367 Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less
M0010 Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services
96365 Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less
99212 Established patient office or other outpatient visit with straightforward medical decision making, if using time, 10 minutes or more
96372 Injection of drug or substance under skin or into muscle
J3489 Injection, zoledronic acid, 1 mg
96415 Administration of chemotherapy into vein, each additional hour
85055 Reticulated (young) platelet measurement
85007 Microscopic examination for white blood cells with manual cell count
85027 Complete blood cell count (red cells, white blood cell, platelets), automated test
71260 Ct scan of chest with contrast
J1200 Injection, diphenhydramine hcl, up to 50 mg
96417 Administration of additional new drug or substance into vein, 1 hour or less
99204 New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more
74177 Ct scan of abdomen and pelvis with contrast
99205 New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more
J7030 Infusion, normal saline solution , 1000 cc
J1454 Injection, fosnetupitant 235 mg and palonosetron 0.25 mg
85045 Red blood count, automated test
96361 Infusion into a vein for hydration, each additional hour
96523 Irrigation of implanted venous access drug delivery device
96402 Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle
A9552 Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries
78815 Nuclear medicine study from skull base to mid-thigh with ct scan
96360 Infusion into a vein for hydration, 31-60 minutes
J3490 Unclassified drugs

These are this provider's own Medicare Part B fee-for-service volumes (CMS public data). CMS suppresses rows with fewer than 11 beneficiaries, so low-volume codes may be missing entirely — absence is not zero. Beneficiary-episodes count CMS's per-setting beneficiary figures, not unique patients. Average charge and average Medicare payment are weighted by service volume across office and facility settings. Volumes on this page are personal to the NPI and are not attributed to any physician group. See Methods & Sources.